Bhuvana Sunil
Tacoma, WANPI 1457756926
Payments from drug & device makers
$543,003in general payments, 2019–2025
Across 689 payments — averaging $788.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$177K
- Medtronic$114K
- Rhythm Pharmaceuticals, Inc.$77K
- Sanofi US Services Inc.$70K
- AbbVie$53K
- Antares Pharma, Inc.$31K
- plus $21K from 9 others
$11,200in research payments, 2019–2025
Across 4 payments — averaging $2800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$9K
- Sanofi-aventis U.S. LLC$2K
General payments by program year
19
20
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 541 | $177,044 |
| Medtronic | 36 | $113,773 |
| Rhythm Pharmaceuticals, Inc. | 26 | $76,512 |
| Sanofi US Services Inc. | 9 | $70,439 |
| AbbVie | 23 | $52,955 |
| Antares Pharma, Inc. | 5 | $31,372 |
| OPKO Pharmaceuticals, LLC | 1 | $19,979 |
| Novo Nordisk | 34 | $403 |
| Sanofi-aventis U.S. LLC | 1 | $250 |
| Amphastar Pharmaceuticals, Inc. | 5 | $102 |
| Abbott | 1 | $50 |
| Sequel Med Tech, LLC | 2 | $45 |
| Insulet Corporation | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $12 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.